SSSimone Schrodi

Simone Schrodi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Simone Schrodi has a total of 46 co-authors. Here are the top co-authors by number of shared publications:

  • J. Engel

    Munich Cancer Registry (MCR) at the Institute of Medical Information Processing, Biometry, and Epidemiology (IBE), Ludwig-Maximilians-University (LMU), Bavarian Cancer Registry - Regional Centre Munich, Bavarian Health and Food Safety Authority (LGL), Munich, Germany

    4 shared publications
  • Carsten Werner

    Leibniz‐Institut für Polymerforschung Dresden e.V. Dresden Germany

    3 shared publications
  • Anett Tillack

    Cancer Centre Brandenburg, Onkologischer Schwerpunkt Frankfurt (Oder), Frankfurt (Oder), Germany

    2 shared publications
  • Antje Niedostatek

    Regional Clinical Cancer Register Dresden (RKKRD), Dresden, Germany

    2 shared publications
  • D. Hölzel

    Tumorregister München (TRM) des Tumorzentrums München (TZM) am Institut für medizinische Informationsverarbeitung, Biometrie und Epidemiologie (IBE)

    2 shared publications
  • G. Schenkirsch

    Tumorzentrum Augsburg

    2 shared publications

Latest Publications

  • Open Access

    Outcome of breast cancer patients with low hormone receptor positivity: analysis of a 15-year population-based cohort

    by S. Schrodi, M. Braun, A. Andrulat, N. Harbeck, S. Mahner, M. Kiechle, E. Klein, A. Schnelzer, C. Schindlbeck, I. Bauerfeind, et al.


  • Open Access

    Role of postoperative radiotherapy in reducing ipsilateral recurrence in DCIS: an observational study of 1048 cases

    by Stefanie Corradini, Montserrat Pazos, Stephan Schönecker, Daniel Reitz, Maximilian Niyazi, Ute Ganswindt, Simone Schrodi, Michael Braun, Martin Pölcher, Sven Mahner, et al.

    The objective of the present study was to evaluate the effectiveness of postoperative radiotherapy after breast conserving surgery (BCS) in DCIS in a large patient population treated in clinical practice. Data were provided by the population-based Munich Cancer Registry. Between 1998 and 2014, 1048 female patients with diagnosis of DCIS and treated at two Breast Care Centres were included in this observational study. The effectiveness of postoperative radiotherapy and variables predicting the use of radiotherapy were retrospectively analysed. After adjusting for age, tumour characteristics and therapies, Cox regression analysis for local recurrence-free survival identified RT as an independent predictor for improved local control (HR: 0.579; 95%CI: 0.384–0.872, p = 0.008). Ten-year cumulative incidence of in-breast recurrences was 20.0% following BCS, compared to 13.6% in patients receiving postoperative radiotherapy (p = 0.012). As an estimate for disease-specific survival, 10-year relative survival was 105.4% for patients receiving postoperative radiotherapy and 101.6% without radiotherapy. On multivariate analysis, postoperative radiotherapy was not associated with improved overall survival (HR 0.526; 95%CI: 0.263–1.052, p = 0.069). Over time, a significant increase of RT was registered: while 1998 only 42.9% of patients received postoperative radiotherapy, the proportion rose to 91.2% in 2014. Women aged < 50 years (OR: 2.559, 95%CI: 1.416–4.625, p < 0.001) or with negative hormone receptor status (OR: 2.625, 95%CI: 1.458–4.728, p = 0.001) or receiving endocrine therapy (OR: 1.762, 95%CI: 1.060–2.927, p = 0.029) were more likely to receive postoperative radiotherapy after BCS. In conclusion, this study provides insights regarding the adoption and treatment pattern of postoperative RT following BCS for DCIS in a large cohort reflecting “real-life” clinical practice in this setting. Postoperative RT was found to be associated with a reduced risk of ipsilateral recurrence and no survival benefit compared to observation alone.


  • Reply to Kowalski C, Wesselmann S, Kuhr K, Wallwiener D, & Kreienberg R

    by Simone Schrodi, Anett Tillack, Antje Niedostatek, Carmen Werner, Gabriele Schubert-Fritschle, Jutta Engel

  • No Survival Benefit for Patients with Treatment in Certified Breast Centers-A Population-based Evaluation of German Cancer Registry Data

    by Simone Schrodi, Anett Tillack, Antje Niedostatek, Carmen Werner, Gabriele Schubert-Fritschle, Jutta Engel

    Much time and money has been spent on the establishment and preservation of certified breast centers (CBCs), but up to now there is almost no evidence for whether certification results in an improved outcome for breast cancer patients. The aim of this evaluation was to assess, whether the certification of specialized units had any influence on their patients’ outcomes and if a survival difference between CBC patients and non-CBC patients can be shown. This population-based analysis included cancer registry data from 32,789 operated breast cancer patients with no prior cancer diagnosis and with active follow-up. They were diagnosed between 2004 and 2010 in four different regions in Germany. Survival was investigated using the Kaplan–Meier method and multivariate Cox regression analysis. A survival difference was found neither between patients with treatment before and after certification of specialized units nor between CBC patients and non-CBC patients aged up to 75 years. Only for patients older than 75 years, an improved survival could be seen for CBC patients (adjusted hazard ratio 0.77; 95% confidence interval 0.68–0.87). The improved survival of elderly CBC patients is most likely caused by selection effects concerning health status differences and not by processes attributable to certification. Thus, this study found that as of yet, certification has not influenced survival of breast cancer patients.


  • Is primary surgery of breast cancer patients consistent with German guidelines? Twelve-year trend of population-based clinical cancer registry data

    by S. Schrodi, A. Niedostatek, C. Werner, A. Tillack, G. Schubert-Fritschle, J. Engel

    This population‐based analysis aimed to describe the 12‐year trend of primary surgery following the introduction of national guidelines for the management of breast cancer in Germany, thus the implementation of breast‐conserving surgery (BCS) for pT1/2‐tumours and the implementation of sentinel lymph node biopsy (SLNB). Cancer registry data from 72 742 breast cancer patients diagnosed between 1999 and 2010 in four different regions in Germany were used. Descriptive statistics and multivariate logistic regression analysis were conducted. Between 1999 and 2010, rates of BCS for pT1/2‐tumours rose from 60.5% to 79.9%, rates of SLNB increased rapidly from 0.4% to 79.0%. Both surgical therapies were already adherent to the respective guidelines, although some regional differences could be observed: in 1999–2003, the chance of BCS was 2.6‐fold higher [odds ratio (OR) 2.6] in the western regions than in the eastern regions, but this difference decreased over time (2004–2007 OR 1.6; 2008–2010 OR 1.2). A similar pattern was observable for SLNB: in 1999–2003, the chance of receiving SLNB was 4.4‐fold higher in the western regions, but these rates converged (2004–2007 OR 3.7; 2008–2010 OR 1.5). The further increase of BCS‐ and SLNB rates after publication of guidelines and the reduction of regional differences may also be attributable to guideline implementation.


  • Veränderungen der Therapie des Mammakarzinoms in Bayern seit Einführung des Mammografie-Screenings. Eine Analyse bayerischer Krebsregisterdaten der Jahre 2000 bis 2008

    by S. Schrodi, U. Braisch, G. Schenkirsch, T. Maisel, S. Petsch, D. Hölzel, M. Klinkhammer-Schalke, U. Mäder, L. Schuller, S. H. Heywang-Köbrunner, et al.

    Ziel: Ende 2003 startete in Bayern, einer Region mit 12,5 Millionen Einwohnern, ein qualitätsgesichtertes Mammografie-Screening-Programm, das Ende 2006 in das bundesweite Screening überging. Ziel der Studie war eine bevölkerungsbezogene Analyse von ersten Auswirkungen des Mammografie-Screenings auf die Therapien des Mammakarzinoms. Methoden: In die Analyse gingen 75 475 in den 6 bayerischen klinischen Krebsregistern gemeldete Brustkrebsfälle der Diagnosejahre 2000 bis 2008 ein, wovon 51,4 % auf die Altersgruppe 50 – 69 Jahre und somit auf die anspruchsberechtigten Frauen entfielen. Die Trends der Prognosefaktoren und Standardtherapien wurden für 3 Altersgruppen (bis 49 Jahre, 50 – 69 Jahre, ab 70 Jahre) anhand der jährlichen prozentualen Verteilungen sowie der 95 %-Konfidenzintervalle für die Differenz der Anteile der Diagnosejahre 2000 und 2008 analysiert. Für die Interpretation der Therapietrends wurden logistische Regressionsmodelle verwendet. Ergebnisse: Die Trends der Standardtherapien zeigen, dass die beobachteten zunehmend günstigeren Stadienverteilungen dazu beigetragen haben könnten, dass insbesondere bei den 50- bis 69-jährigen Frauen signifikant häufiger auf radikale Operationsverfahren wie Mastektomie (2000: 32,6 %; 2008: 19,6 %) oder Axilladissektion (89,0 % vs. 37,0 %) verzichtet wird. Die Zunahme der durchgeführten Strahlentherapien (59,7 % vs. 66,6 %) ist dabei zum Teil eine Folge der zunehmenden brusterhaltenden Operationen. Die Verschiebung hin zu günstigeren Prognosefaktoren führt leitliniengerecht zu einer Zunahme des Anteils alleiniger endokriner Therapien (28,5 % vs. 40,7 %), einem Rückgang des Anteils alleiniger Chemotherapien (20,4 % vs. 13,1 %) und damit insgesamt zu schonenderen systemischen Therapien. Diese Trends verstärken sich in den Folgejahren nach Einführung des Screenings, bei gleichzeitigem Anstieg des Anteils der Screeningteilnehmerinnen in der Zielbevölkerung. Schlussfolgerung: Mit Einführung des Mammografie-Screenings in Bayern zeigt sich der erwartete Trend zu günstigeren Prognosefaktoren, was u. a. auch zu den zunehmend schonenderen Therapien geführt haben könnte. Ob das Mammografie-Screening-Programm in Bayern das angestrebte Ziel der Reduktion der Sterblichkeit an Brustkrebs erreicht, ist zuerst mit Krebsregistervergleichen nach Teilnahmestatus zu analysieren und später mit dem Trend der Mortalität. Purpose: A quality controlled mammography screening programme was initiated at the end of 2003 in Bavaria, a region with 12.5 million inhabitants, and transferred over to the national screening programme at the end of 2006. The purpose of this study was to evaluate immediate population-based consequences of mammography screening on breast cancer therapy. Methods: Data from 75 475 breast cancer cases, diagnosed between 2000 and 2008 and registered in one of the 6 Bavarian clinical cancer registries were analysed. 51.4 % of these patients were between 50 and 69 years of age and therefore the target population for screening. Trends of prognostic factors and standard therapies were calculated for 3 age groups (≤ 49 years, 50 – 69 years, ≥ 70 years) by means of annual percentages as well as 95 %-confidence intervals for the percent difference between 2000 and 2008 (year of diagnosis). For interpretation of therapy trends, logistic regression models were calculated. Results: Therapy trends showed that the increasingly favourable stage distribution may have resulted in the reduction of more radical surgical methods such as mastectomy (2000: 32.6 %; 2008: 19.6 %) or axillary dissection (89.0 % vs. 37.0 %), especially for women aged 50 – 69. An increase of radiation therapies (59.7 % vs. 66.6 %) can be explained to some extent by the increase in breast conserving surgeries. The shift to more favourable prognostic factors led, in accordance with the guidelines, to an increase of the proportion of singular endocrine therapies (28.5 % vs. 40.7 %), a decrease of chemotherapies (20.4 % vs. 13.1 %) and therefore to more gentle systemic therapies overall. These trends strengthened in the years following the introduction of screening, with a simultaneous rise of screening participants in the target population. Conclusion: The introduction of mammography screening in Bavaria has already shown the expected trend towards more favourable prognostic factors. Among other things, this could be a reason for the increasing use of more gentle therapies. Whether the screening in Bavaria leads to a mortality reduction, has to be analysed on the basis of an initial comparison of participation status followed by the trends in mortality thereafter.

  • Veränderungen der Therapie des Mammakarzinoms in Bayern seit Einführung des Mammografie-Screenings. Eine Analyse bayerischer Krebsregisterdaten der Jahre 2000 bis 2008

    by S. Schrodi, U. Braisch, G. Schenkirsch, T. Maisel, S. Petsch, D. Hölzel, M. Klinkhammer-Schalke, U. Mäder, L. Schuller, S. H. Heywang-Köbrunner, et al.

    Ende 2003 startete in Bayern, einer Region mit 12,5 Millionen Einwohnern, ein qualitätsgesichtertes Mammografie-Screening-Programm, das Ende 2006 in das bundesweite Screening überging. Ziel der Studie war eine bevölkerungsbezogene Analyse von ersten Auswirkungen des Mammografie-Screenings auf die Therapien des Mammakarzinoms. In die Analyse gingen 75 475 in den 6 bayerischen klinischen Krebsregistern gemeldete Brustkrebsfälle der Diagnosejahre 2000 bis 2008 ein, wovon 51,4% auf die Altersgruppe 50–69 Jahre und somit auf die anspruchsberechtigten Frauen entfielen. Die Trends der Prognosefaktoren und Standardtherapien wurden für 3 Altersgruppen (bis 49 Jahre, 50–69 Jahre, ab 70 Jahre) anhand der jährlichen prozentualen Verteilungen sowie der 95%-Konfidenzintervalle für die Differenz der Anteile der Diagnosejahre 2000 und 2008 analysiert. Für die Interpretation der Therapietrends wurden logistische Regressionsmodelle verwendet. Die Trends der Standardtherapien zeigen, dass die beobachteten zunehmend günstigeren Stadienverteilungen dazu beigetragen haben könnten, dass insbesondere bei den 50- bis 69-jährigen Frauen signifikant häufiger auf radikale Operationsverfahren wie Mastektomie (2000: 32,6%; 2008: 19,6%) oder Axilladissektion (89,0% vs. 37,0%) verzichtet wird. Die Zunahme der durchgeführten Strahlentherapien (59,7% vs. 66,6%) ist dabei zum Teil eine Folge der zunehmenden brusterhaltenden Operationen. Die Verschiebung hin zu günstigeren Prognosefaktoren führt leitliniengerecht zu einer Zunahme des Anteils alleiniger endokriner Therapien (28,5% vs. 40,7%), einem Rückgang des Anteils alleiniger Chemotherapien (20,4% vs. 13,1%) und damit insgesamt zu schonenderen systemischen Therapien. Diese Trends verstärken sich in den Folgejahren nach Einführung des Screenings, bei gleichzeitigem Anstieg des Anteils der Screeningteilnehmerinnen in der Zielbevölkerung. Mit Einführung des Mammografie-Screenings in Bayern zeigt sich der erwartete Trend zu günstigeren Prognosefaktoren, was u. a. auch zu den zunehmend schonenderen Therapien geführt haben könnte. Ob das Mammografie-Screening-Programm in Bayern das angestrebte Ziel der Reduktion der Sterblichkeit an Brustkrebs erreicht, ist zuerst mit Krebsregistervergleichen nach Teilnahmestatus zu analysieren und später mit dem Trend der Mortalität. A quality controlled mammography screening programme was initiated at the end of 2003 in Bavaria, a region with 12.5 million inhabitants, and transferred over to the national screening programme at the end of 2006. The purpose of this study was to evaluate immediate population-based consequences of mammography screening on breast cancer therapy. Data from 75 475 breast cancer cases, diagnosed between 2000 and 2008 and registered in one of the 6 Bavarian clinical cancer registries were analysed. 51.4% of these patients were between 50 and 69 years of age and therefore the target population for screening. Trends of prognostic factors and standard therapies were calculated for 3 age groups (≤49 years, 50–69 years, ≥70 years) by means of annual percentages as well as 95%-confidence intervals for the percent difference between 2000 and 2008 (year of diagnosis). For interpretation of therapy trends, logistic regression models were calculated. Therapy trends showed that the increasingly favourable stage distribution may have resulted in the reduction of more radical surgical methods such as mastectomy (2000: 32.6%; 2008: 19.6%) or axillary dissection (89.0% vs. 37.0%), especially for women aged 50–69. An increase of radiation therapies (59.7% vs. 66.6%) can be explained to some extent by the increase in breast conserving surgeries. The shift to more favourable prognostic factors led, in accordance with the guidelines, to an increase of the proportion of singular endocrine therapies (28.5% vs. 40.7%), a decrease of chemotherapies (20.4% vs. 13.1%) and therefore to more gentle systemic therapies overall. These trends strengthened in the years following the introduction of screening, with a simultaneous rise of screening participants in the target population. The introduction of mammography screening in Bavaria has already shown the expected trend towards more favourable prognostic factors. Among other things, this could be a reason for the increasing use of more gentle therapies. Whether the screening in Bavaria leads to a mortality reduction, has to be analysed on the basis of an initial comparison of participation status followed by the trends in mortality thereafter.